Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 19;9(1):70.
doi: 10.1038/s41523-023-00576-5.

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Paul E Hanna  1 , Ian A Strohbehn  1 , Daiana Moreno  1 , Destiny Harden  1 , Rituvanthikaa Seethapathy  1 , Rani Sawtell  1 , Qiyu Wang  1 , Tianqi Ouyang  1 , Nurit Katz-Agranov  1 , James Dinulos  1 , Seth A Wander  2 , Shruti Gupta  3   4 , Meghan E Sise  5
Affiliations

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Paul E Hanna et al. NPJ Breast Cancer. .

Abstract

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.

PubMed Disclaimer

Conflict of interest statement

P.E.H., I.A.S., D.M., D.H., R.S., R.S., Q.W., T.O., N.K. and J.D. have nothing to disclose. S.G. receives research funding from BTG International and GE Healthcare. S.G. serves as a consultant for GlaxoSmithKline and Secretome. S.W. serves on the consulting/advisory board of the following organizations: Foundation Medicine, Veracyte, Hologic, Pfizer, Eli Lilly, Biovica; Institutional research support: Genentech, Eli Lilly, Nuvation Bio, and Regor Therapeutics. M.E.S. has research funding from Gilead, Abbvie, Otsuka, Angion, and EMD Serono. M.E.S. has served on an advisory board for Vera, Novartis, Travere, and Malinckrodt, and she is a Data Monitoring Committee Member for Alpine Immunosciences.

Figures

Fig. 1
Fig. 1. Mean monthly eGFR for the first year of treatment in patients receiving CDK4/6 inhibitors vs. aromatase inhibitors alone.
Average eGFR by month and 95% confidence interval bars are shown. There was no significant difference between mean eGFR at month 12 among recipients of abemaciclib (N = 67), palbociclib (N = 201), or aromatase inhibitors alone (N = 63); one-way ANOVA test p = 0.59. Ribociclib-treated patients were excluded from this analysis due to low numbers, only 6 survived to 12 months; shown in Supplemental Fig. 2. eGFR estimated glomerular filtration rate.
See this image and copyright information in PMC

References

    1. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 2016;13:417–430. doi: 10.1038/nrclinonc.2016.26. - DOI - PubMed
    1. Sy-Go JPT, Yarandi N, Schwartz GL, Herrmann SM. Ribociclib-induced pseudo-acute kidney injury. J. Onco-Nephrol. 2022;6:64–69. doi: 10.1177/23993693221085285. - DOI
    1. Bonilla M, Bashir KA, Jhaveri KD. An elevated serum creatinine in a patient receiving palbociclib. J. Onco-Nephrol. 2021;5:133–135. doi: 10.1177/23993693211021420. - DOI
    1. Chappell JC, et al. Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin. Pharm. Ther. 2019;105:1187–1195. doi: 10.1002/cpt.1296. - DOI - PMC - PubMed
    1. Gupta S, Caza T, Herrmann SM, Sakhiya VC, Jhaveri KD. Clinicopathologic features of acute kidney injury associated with CDK4/6 inhibitors. Kidney Int. Rep. 2022;7:618–623. doi: 10.1016/j.ekir.2021.11.033. - DOI - PMC - PubMed